JP2008510716A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510716A5
JP2008510716A5 JP2007528019A JP2007528019A JP2008510716A5 JP 2008510716 A5 JP2008510716 A5 JP 2008510716A5 JP 2007528019 A JP2007528019 A JP 2007528019A JP 2007528019 A JP2007528019 A JP 2007528019A JP 2008510716 A5 JP2008510716 A5 JP 2008510716A5
Authority
JP
Japan
Prior art keywords
formulation
antagonist
lyophilized
reconstituted
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007528019A
Other languages
English (en)
Japanese (ja)
Other versions
JP4948410B2 (ja
JP2008510716A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/029428 external-priority patent/WO2006023665A2/en
Publication of JP2008510716A publication Critical patent/JP2008510716A/ja
Publication of JP2008510716A5 publication Critical patent/JP2008510716A5/ja
Application granted granted Critical
Publication of JP4948410B2 publication Critical patent/JP4948410B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007528019A 2004-08-17 2005-08-17 Il−1アンタゴニスト製剤 Expired - Fee Related JP4948410B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60213704P 2004-08-17 2004-08-17
US60/602,137 2004-08-17
PCT/US2005/029428 WO2006023665A2 (en) 2004-08-17 2005-08-17 Il-1 antagonist formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012013973A Division JP2012121894A (ja) 2004-08-17 2012-01-26 Il−1アンタゴニスト製剤

Publications (3)

Publication Number Publication Date
JP2008510716A JP2008510716A (ja) 2008-04-10
JP2008510716A5 true JP2008510716A5 (https=) 2008-05-22
JP4948410B2 JP4948410B2 (ja) 2012-06-06

Family

ID=35968186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007528019A Expired - Fee Related JP4948410B2 (ja) 2004-08-17 2005-08-17 Il−1アンタゴニスト製剤
JP2012013973A Pending JP2012121894A (ja) 2004-08-17 2012-01-26 Il−1アンタゴニスト製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012013973A Pending JP2012121894A (ja) 2004-08-17 2012-01-26 Il−1アンタゴニスト製剤

Country Status (14)

Country Link
US (1) US7365165B2 (https=)
EP (2) EP2311871A3 (https=)
JP (2) JP4948410B2 (https=)
CN (1) CN101014617B (https=)
AU (1) AU2005277357B2 (https=)
BR (1) BRPI0514411B8 (https=)
CA (1) CA2576519C (https=)
DK (1) DK1778723T3 (https=)
ES (1) ES2395035T3 (https=)
PL (1) PL1778723T3 (https=)
PT (1) PT1778723E (https=)
SI (1) SI1778723T1 (https=)
WO (1) WO2006023665A2 (https=)
ZA (1) ZA200701529B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
ES2985784T3 (es) 2011-11-18 2024-11-07 Regeneron Pharma Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
EP2834262B1 (en) * 2012-04-04 2020-09-02 Polaris Group Composition comprising pegylated arginine deiminase
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
KR20190053908A (ko) 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
TWI784982B (zh) 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4172842B2 (ja) * 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants

Similar Documents

Publication Publication Date Title
JP2008510716A5 (https=)
JP2013079270A5 (https=)
JP2009540001A5 (https=)
RU2011127913A (ru) Составы, содержащие антитела
US12186384B2 (en) Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
JP2012515221A5 (https=)
Kawasaki et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects
JP2009524595A5 (https=)
JP2012121894A (ja) Il−1アンタゴニスト製剤
CN102202688B (zh) 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
WO2008150479A3 (en) High temperature stable peptide formulation
JP2013511557A5 (https=)
JP2019506406A5 (https=)
RU2012125254A (ru) Составы антитела
JP2024001364A5 (https=)
CA2272245A1 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
JP2012531442A5 (https=)
FI3408295T3 (fi) Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus
CA2635998A1 (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
CN108785654A (zh) 脂肽组合物和相关方法
RU2008148830A (ru) Препарат вакцины на основе конъюгата никотин-носитель
JP2011530524A5 (https=)
JP2016520075A5 (https=)
US20250057936A1 (en) Vaccine composition